Clinical Trials Logo

Ranibizumab clinical trials

View clinical trials related to Ranibizumab.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04062370 Not yet recruiting - Clinical trials for Retinal Vein Occlusion

Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion

Start date: October 1, 2019
Phase: Phase 4
Study type: Interventional

Retinal vein occlusion (RVO) may lead to series of complications including retinal ischemia, macular edema (ME) and induce vision impairment. Intravitreal injection of Ranibizumab (0.5mg) has been proved to be a safe and effective method for the treatment of RVO-ME. In this study, different treatment regimens of Ranibizumab is applied and the effects is observed at 1-6 months to explore the best regimen for RVO. After 6 months, anti-VEGF therapy and/or laser photocoagulation is used to explore whether laser photocoagulation can maintain the therapeutic effect of Ranibizumab or reduce the injection number.

NCT ID: NCT03452657 Not yet recruiting - Clinical trials for Diabetic Retinopathy

Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)

Start date: April 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of intravitreous ranibizumab treatment versus sham injections for prevention of high-risk DR.

NCT ID: NCT02914626 Not yet recruiting - Clinical trials for Glaucoma, Neovascular

Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

Start date: October 2016
Phase: Phase 3
Study type: Interventional

Neovascular glaucoma is a potentially blinding condition characterized by the growth of newvessels at the anterior part of the eye. This growth is driven by the overexpression of a protein called Vascular Endothelial Growth Factor (VEGF). That happens in diseases such as diabetic retinopathy or venous retinal occlusion, and lead to a fast increase in intraocular pressure (IOP). Traditional treatment include laser photocoagulation of the retina in order to decrease VEGF formation. The investigators postulate that the use of anti-VEGF intravitreal injections may accelerate recovery and decrease the need of surgery in cases of neovascular glaucoma.